Dr Reddy consolidated revenue for the quarter came in at Rs. 3612 crore, registering 4.8% yoy decline. This was mainly driven by 7% yoy decrease in Pharmaceutical services.
EBITDA for the quarter rose by 22.6% yoy to Rs. 591 crore with a corresponding margin expansion of 366 bps. EBITDA margin for the quarter stood at 16.4%. This margin expansion was driven by decrease in cost of raw material and other expenses by 24% yoy and 16.6% yoy respectively.
The PAT for the quarter came in at Rs. 327 crore, yoy increase of 179%.
EBITDA for the quarter rose by 22.6% yoy to Rs. 591 crore with a corresponding margin expansion of 366 bps. EBITDA margin for the quarter stood at 16.4%. This margin expansion was driven by decrease in cost of raw material and other expenses by 24% yoy and 16.6% yoy respectively.
The PAT for the quarter came in at Rs. 327 crore, yoy increase of 179%.
Looking at the full year numbers, we see that revenue slided by 9% to reach Rs.14196.1 crore while EBITDA fell by 31% to 2472.2 crore. Company reported net profit of Rs.1257.2 crore, down 40% yoy.
The Board of Directors have recommended a final dividend of Rs. 20 per equity share for the face value of Rs. 5 each for FY16-17.
Technical View:
Dr Reddys Laboratories Ltd is currently trading at Rs. 2585.75, down by 6.65 points or 0.26% from its previous closing of Rs. 2592.4 on the BSE.
The scrip opened at Rs. 2593 and has touched a high and low of Rs. 2608 and Rs. 2525.25 respectively. So far 818449(NSE+BSE) shares were traded on the counter. The stock is currently trading above its 200 DMA.
The Board of Directors have recommended a final dividend of Rs. 20 per equity share for the face value of Rs. 5 each for FY16-17.
Technical View:
Dr Reddys Laboratories Ltd is currently trading at Rs. 2585.75, down by 6.65 points or 0.26% from its previous closing of Rs. 2592.4 on the BSE.
The scrip opened at Rs. 2593 and has touched a high and low of Rs. 2608 and Rs. 2525.25 respectively. So far 818449(NSE+BSE) shares were traded on the counter. The stock is currently trading above its 200 DMA.
No comments:
Post a Comment